CGTX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Stats
今日成交量	63 329.00
平均成交量	199 883
市值	75.27M
EPS	$0 ( 2024-03-26 )
下一个收益日期	( $-0.250 ) 2024-06-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.24
ATR14	$0.0130 (0.67%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Doyle John Brendan	Sell	8 699	Common Stock
2024-03-14	Ricciardi Lisa	Buy	5 700	Common Stock
2024-02-15	Doyle John Brendan	Buy	20 000	Common Stock
2024-02-15	Doyle John Brendan	Buy	20 000	Stock Option (Right to Buy)
2024-02-15	Caggiano Anthony	Buy	60 000	Common Stock

INSIDER POWER
96.32
Last 94 transactions
Buy: 12 485 685 \| Sell: 1 489 688

音量相关性

長: 0.16 (neutral)

短: 0.18 (neutral)

Signal:(52.627) Neutral

Cognition Therapeutics, 相关性

10 最正相关
BOWXU	0.909
AYLA	0.897
AGCUU	0.896
ASPS	0.896
IRBT	0.894
ARQQ	0.878
AMD	0.876
CELU	0.875
OP	0.873
SNPS	0.872

10 最负相关
IVAC	-0.894
ULTA	-0.889
ISEM	-0.884
PAHC	-0.882
CTLP	-0.879
RCM	-0.877
WFRD	-0.876
STAY	-0.872
IQ	-0.872
IDLB	-0.865

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Cognition Therapeutics, 相关性 - 货币/商品

-0.38
( neutral )

0.31
( neutral )

0.00
( neutral )

-0.49
( neutral )

0.40
( neutral )

-0.59
( weak negative )

Cognition Therapeutics, 财务报表

Annual	2023
营收:	$0
毛利润:	$-252 000 (0.00 %)
EPS:	$-0.860

FY	2023
营收:	$0
毛利润:	$-252 000 (0.00 %)
EPS:	$-0.860

FY	2022
营收:	$0
毛利润:	$-235 000 (0.00 %)
EPS:	$0.0261

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.548

Financial Reports:

No articles found.

Cognition Therapeutics,

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.